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Abstract: Radiation therapy (RT) is a curative treatment modality for localized prostate cancer. Over the
past two decades, advances in technology and imaging have considerably changed RT in prostate cancer
treatment. Treatment has evolved from 2-dimensional (2D) planning using X-ray fields based on pelvic
bony landmarks to 3-dimensional (3D) conformal RT (CRT) which uses computed tomography (CT) based
planning. Despite improvements with 3D-CRT, dose distributions often remained suboptimal with portions
of the rectum and bladder receiving unacceptably high doses. In more recent years, intensity-modulated
radiation therapy (IMRT) has become the standard of care to deliver external beam RT. IMRT uses multiple
radiation beams of different shapes and intensities delivered from a wide range of angles to ‘paint’ the
radiation dose onto the tumor. IMRT allows for a higher dose of radiation to be delivered to the prostate
while reducing dose to surrounding organs. Multiple clinical trials have demonstrated improved cancer
outcomes with dose escalation, but toxicities using 3D-CRT and escalated doses have been problematic.
IMRT is a method to deliver dose escalated RT with more conformal dose distributions than 3D-CRT and
has been associated with improved toxicity profiles. IMRT also appears to be the safest method to deliver
hypofractionated RT and pelvic lymph node radiation. The purpose of this review is to summarize the
technical aspects of IMRT planning and delivery, and to review the literature supporting the use of IMRT
for prostate cancer.
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Introduction
Prostate cancer is the most common malignancy in
men (1). Patients with localized prostate cancer have
multiple treatment options including active surveillance,
prostatectomy, brachytherapy, and external beam radiation
therapy (EBRT). A patient’s preference toward a specific
treatment is often driven by the invasiveness of the
treatment modality and the expected side effects from that
particular intervention. EBRT, considered as one of the
least invasive treatments, has changed drastically over the
past several decades with the ultimate goal of improving
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survival outcomes with decreasing toxicity. Older techniques
were replaced with 3-dimensional (3D) conformal radiation
therapy (CRT), and further technological advancements
in radiation imaging, planning, and delivery has allowed
the introduction and wide adoption of intensity-modulated
radiation therapy (IMRT). IMRT uses 3D imaging to guide
beams of radiation to the tumor from many different angles
while changing (modulating) the intensity and shape of the
beam to match the shape of the tumor. These adjustments
of the radiation allow for the prescribed amount of radiation
to be delivered to each part of the tumor while minimizing
the amount of radiation normal surrounding healthy tissue
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receives. For prostate cancer, multiple randomized and
nonrandomized series have shown improved tumor control
with the use of dose escalated therapy (2-7). The enhanced
conformality of IMRT allow for dose escalation to the
prostate while reducing dose to the bladder and rectum,
and trials have demonstrated reduced toxicity with IMRT
(8,9). In addition to the fundamental principles of the
IMRT technique, there are numerous biologic, anatomic,
and clinical features which also make prostate cancer a
model site for implementation of IMRT. In this review,
we describe the evolution of EBRT to IMRT, describe the
specific features of prostate cancer which make this disease
an ideal site for implementation and routine use of IMRT,
comparisons between IMRT and 3D-CRT including
genitourinary (GU) and gastrointestinal (GI) toxicities,
clinical outcomes of IMRT including dose escalation, and
future directions utilizing this technology.
Evolution of external beam radiation to IMRT
Historically, definitive radiation for prostate cancer was
accomplished using 2-dimensional (2D) or 3D-CRT. The
most common conventional beam arrangement was a “four
field box” arrangement consisting of a pair of anteriorposterior and posterior-anterior (AP-PA) beams, as well as a
pair of lateral opposed beams. This approach was commonly
used into the early 1990s, until 3D-CRT became more
widely adopted. 3D-CRT takes advantage of sophisticated
computer software, and included computed tomography
(CT) simulation to integrate volumetric data regarding the
patient’s tumor and organs at risk to allow for beam angles
and radiation portals that were difficult to implement using
conventional 2-dimensional planning.
Dearnaley et al. conducted a randomized study of
conventional vs. 3D-CRT to a dose of 64 Gy in 2 Gy
fractions, which at that time was a standard dose for
prostate cancer (10). Of the 225 men treated, significantly
fewer men developed radiation proctitis and bleeding in the
3D-CRT group compared to the conventional group (5%
vs. 15% grade 2+) and there was no difference in tumor
control. As toxicity was reduced with 3D-CRT, several
groups conducted studies to escalate the radiation dose
to the prostate tumor. The outcomes of dose escalation
with 3D-CRT have been summarized in several other
review articles (11-14). In general, they observed that
the radiation dose could be escalated from the range of
64–68 Gy to the range of 74–81 Gy using 3D-CRT, and
resulted in improved biochemical progression free survival
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rates. These results are summarized by a meta-analysis
conducted by Viani et al., which pooled seven randomized
trials with a total patient population of 2,812 (15). They
identified that dose-escalated radiation resulted in
significant reductions in biochemical failure, but there were
no differences in the rate of all-cause or prostate cancer
specific mortality. Furthermore, there were also more cases
of late grade 2+ GI toxicity in the high-dose radiation
groups, with the absolute difference typically ranging
between 5–10% between the study arms.
In particular, the Radiation Therapy Oncology Group
(RTOG) conducted protocol 9406 which used 3D-CRT
to sequentially increase the radiation dose to several
levels including 68.4 (1.8 Gy per fraction), 73.8 (1.8 Gy
per fraction), 79.2 (1.8 Gy per fraction), 74.0 (2.0 Gy per
fraction), and 78.0 (2.0 Gy per fraction) (16). These regimens
resulted in disease free and biochemical progression free
survival rates which compared favorably with historical data.
Additionally, the toxicity results with 3D-CRT, including
the maximum dose levels of 79.2 Gy in 1.8 Gy per fraction
and 78.0 Gy in 2.0 Gy per fraction were low compared
to historical controls (17). However, the 78 Gy in 2.0 Gy
fractions dose level was ultimately associated with a greater
incidence of late grade 2+ toxicity compared to 79.2 Gy
in 1.8 Gy per fraction (30–33% vs. 9–13%). These results
established a dose of 79.2 Gy in 1.8 Gy fractions for prostate
cancer that is commonly used at Washington University in
St. Louis.
An additional refinement on 3D-CRT is a technique
known as IMRT. IMRT uses beam modulation and “field
in field” techniques made possible by multi-leaf collimators
combined with sophisticated inverse planning software. The
IMRT approach allows the radiation oncologist to prescribe
doses to target structures such as the prostate and proximal
seminal vesicles and dose constraints to nearby normal
structures such as the rectum and bladder. The computer
software then determines the beam modulation to optimally
achieve the radiation prescription. The resulting radiation
distribution appears “sculpted” to cover the target and to
avoid normal structures in a way that would typically not be
achievable using conventional planning methods as seen in
Figure 1. Although the mathematics underlying IMRT were
published in the late 1980s and early 1990s, clinical IMRT
systems were not implemented until the mid to late 1990s
and commercial systems were not in common use until the
early 2000s.
There are no randomized controlled trials directly
comparing dose escalated IMRT and 3D-CRT in prostate
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Table 1 Target and normal structure constraints used for prostate
IMRT optimization at Washington University in St. Louis. For
example, the interpretation of the constraint “Rectum V65 Gy
<17%” can be explained as: limit volume of rectum receiving
65 Gy or greater to less than 17 percent of the total volume of the
structure

Figure 1 Illustrative IMRT plan treating the prostate and proximal
seminal vesicles. The images show the radiation dose distribution

Structure

Optimization parameter

Planning target volume
(PTV)

Cover 98% of PTV with 100% of
prescription dose

Rectum

V65 Gy <17% and V40 Gy <35%

Bladder

V65 Gy <25% and V40 Gy <50%

Femoral heads

V50 Gy <10% for each femoral head

Penile bulb

Mean dose <52 Gy

IMRT, intensity-modulated radiation therapy.

in the axial (top center), coronal (bottom left), and sagittal (bottom
right) orientations. The dose color-wash shows the radiation
dose distribution as percentage of the prescription dose. Regions
outside of the color-wash received less than 20% of the radiation
prescription dose. The treatment plan encompasses the prostate
(red structure) and proximal seminal vesicles (green structure) and
avoids nearby regions such as the bladder, rectum, penile bulb, and
femoral heads. The dense structures inside the prostate are fiducial
markers placed for image guidance. The radiation plan includes
seven beam angles and uses beam energy of 10 mega-volts (MV).
IMRT, intensity-modulated radiation therapy.

cancer. However, several single institution retrospective
studies have demonstrated improved biochemical control
and/or reduced GI toxicity with IMRT as compared
to 3D-CRT (18-20). Additionally, in RTOG 0126, a
randomized study of dose escalation in intermediate risk
prostate cancer, a reduction in late grade 2+ GI toxicity
of 15% vs. 22% was observed with IMRT compared to
3D-CRT in the 79.2 Gy high dose arm (8). These studies
will be discussed in detail later in this review.
The reduction in toxicity of IMRT as compared to
3D-CRT has led to its rapid adoption in the United
States. In a SEER-Medicare study, IMRT use increased
substantially as a proportion of patients treated with
radiation from 28% in 2002 to 82% in 2005 (21). According
to the most recent 2016 American College of Radiology
Appropriateness Criteria, the use of 3D-CRT for dose
escalated treatment of prostate cancer is typically no
longer appropriate if other options, such as IMRT, are
available (22).
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Anatomic and biologic features which make
prostate cancer a model site for implementation
of IMRT
The prostate is located in close proximity to the rectum,
bladder, penile bulb, and femoral heads which are at risk
of receiving radiation dose and subsequent toxicity due
to prostate cancer treatment. IMRT has been shown in
dosimetric studies to substantially decrease the amount of
unintentional radiation delivered to these normal structures.
In RTOG 0126, a comparison of the dosimetry of IMRT
and 3D-CRT plans in the 79.2 Gy arm showed that the
percent of the rectum treated to at least 75 Gy (rectum
V75) was reduced from 15.8% to 13.0%, and the V65 was
reduced from 27.4% to 23.0% (8). The bladder V75 was
reduced from 17.7% to 13.1% and the V65 was reduced
from 25.3% to 19.7%. A dosimetric study by Hardcastle
et al. showed similar findings suggesting a reduction in the
rectum V75 from 23.2% to 9.9%, resulting in an estimated
reduction in rectal complication rates from 14% to
5% (23). Luxton et al. have estimated that the mean dose
to the femoral heads can be approximately halved by
using IMRT over 3D-CRT (24). Additional studies have
shown the possibility of IMRT in reducing radiation dose
to the penile bulb (mean dose 33 vs. 49 Gy for IMRT vs.
3D-CRT) (25) The normal structure dose constraints used
for IMRT plan optimization used at Washington University
in St. Louis are listed in Table 1. The ability of IMRT to
reduce dose to nearby normal structures without sacrificing
dose coverage of the target makes it an ideal treatment
modality for prostate cancer.
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There may be additional radiobiological considerations
that make prostate cancer a good target for IMRT,
due to the alpha/beta ratio of the tumor and the use of
hypofractionated radiation treatments. The response
of tumor cells and normal tissue to therapeutic doses of
radiation can be characterized by the alpha/beta ratio
(α/β). This radiobiologic parameter is useful in determining
the effect of various dose and fractionation schemes on
the tissue. In this model, α represents the cells that die
after one “hit” of radiation and β represents the cells that
die after two “hits”, representing the ability to repair
sublethal damage. The ratio of these two parameters, α/β,
represents the “sensitivity” of a tissue to radiation. Rapidly
proliferating cells, such as most tumors, are characterized
by a α/β of ≥10 whereas most normal tissues, which are
comprised of slower proliferating cells, have an α/β of 2–3.
Tissues with low α/β are thought to be more sensitive to
radiation given in large doses per treatment (large fraction
sizes), while tissues with high α/β are thought to be more
responsive to smaller fraction sizes. The combination of
α/β ratio, dose per fraction, and number of fractions in
a radiation treatment course can be used to calculate the
biologically effective dose (BED), which is a measure of
damage to tumor cells that can be calculated from many
different radiation regimens.
Surprisingly, while most tumors have high α/β values,
radiobiological models based on clinical data suggest that
prostate cancer has a low α/β ratio of about 1.5 Gy, which is
actually lower than that of many normal tissues in the pelvis
(26,27). This finding implies that although dose escalation
using conventional fractionation (1.8–2.0 Gy per fraction)
has been effective for prostate cancer, an alternative
method of improving the therapeutic ratio may include
hypofractionation, the use of doses >2.0 Gy per radiation
treatment (28).
The efficacy and toxicity of moderate hypofractionation
has been tested in several studies (29). The United Kingdom
CHHiP study randomized patients to 74 Gy in 2 Gy
fractions vs. two hypofractionated regimens of 60 Gy in 20
fractions or 57 Gy in 19 fractions (29). IMRT was mandated
in this study, and there were no differences in toxicity or
cancer-related outcomes (29,30). The RTOG conducted
a randomized study comparing a dose of 73.8 Gy in
1.8 Gy fractions to moderate hypofractionation to a dose of
70 Gy in 28 fractions (31). This study of 1,092 men with low
risk prostate cancer established that the hypofractionated
regimen was non-inferior in efficacy compared to the
conventional regimen (31). However, there was an increase
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in late GI/GU adverse events with hypofractionated
treatment. Both 3D-CRT and IMRT was allowed on
this study. The Dutch HYPRO study also randomized
patients between a conventional and hypofractionated dose
regimen, and there was a ~95% utilization of IMRT in both
arms (32). The late toxicity results of this study showed
that the incidence of grade 3+ GI toxicity between the two
regimens were not different (2.6% vs. 3.3%), but the late
grade 3+ GU toxicity was not non-inferior between the
conventional and hypofractionated treatments (13% and
19% respectively) (32). Five-year rates of treatment failure
and relapse free survival were not significantly different
between the two groups (32).
Although further analysis and reporting of the data is
needed, the evidence above may suggest that IMRT is
important to the delivery of moderate hypofractionation
without excess GI toxicity. However, the ability of IMRT
to reduce GU toxicity is limited as a portion of the bladder
and prostatic urethra are necessarily within the treatment
volume. Future studies will better define the appropriate
tissue constraints to use for hypofractionated radiation, and
the full benefit of IMRT in this setting.
Technical aspects of IMRT
IMRT combines inverse treatment planning and computercontrolled intensity modulation of the radiation to
deliver 3D-CRT. Since the introduction of IMRT, many
techniques for IMRT treatment of the prostate have been
implemented (33). A common approach is the use of
multiple coplanar fields arranged at equal or nearly equal
spacing around the patient (33). Usually between 5 to 9
static fields are used for this approach, and in general, dose
homogeneity and conformality improve as the number of
treatment fields increases, however the benefit with field
numbers beyond 7 to 9 diminishes (33,34). Noncoplanar
beam arrangements, volumetric-modulated arc therapy
(VMAT) and tomotherapy have been developed in attempts
to further improve the dose distribution and are commonly
used at many institutions.
IMRT treatment plans are designed by using specialized
computer algorithms commonly termed “inverse treatment
planning and optimization” systems (33). The user
selects objectives, usually termed constraints and goals,
that describe the desired dose to each target and organ
at risk, and penalties are assigned based on the relative
importance of each objective (33). These constraints
and penalties are then combined into the mathematical
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Table 2 Randomized trials evaluating external beam radiation therapy dose escalation for localized prostate cancer
Study

Patients

Dose (Gy)

Median follow-up (months)

bDFS

Grade 2+ GI toxicity

MD Anderson

301

78 vs. 70

104

78% vs. 59%*

26% vs. 13%*

PROG 95-09

393

79.2 vs. 70.2

107

83% vs. 68%*

24% vs. 13%

MRC RT01

843

74 vs. 64

120

55% vs. 43%*

33% vs. 24%*

GETUG 06

306

80 vs. 70

61

72% vs. 61%*

20% vs. 14%

Dutch CKVO96-10

669

78 vs. 68

70

54% vs. 47%*

35% vs. 25%*

*, P<0.05. bDFS, biochemical disease-free survival; GI, gastrointestinal.

algorithm according to a cost function and the intensity of
beamlets within each field are adjusted iteratively until the
cost function is minimized and thereby determining the
intensity of each beam that leads to the closest profile as
stated in the objective goals (33). Optimization objectives
are both planning system and patient specific, therefore
many institutions have developed institutional constraint
templates that are used as a starting point for the planning
process (33). The delivery of IMRT is than achieved by using
either sequential delivery of multiple static apertures from a
multileaf collimator (MLC) termed “step and shoot”, or as
dynamic multileaf movement termed “sliding window” (35).
Other techniques for delivery are available, but these two
methods remain the most common.
After an acceptable IMRT plan has been generated, it
is important to ensure the plan is properly implemented.
Delivery of the complex intensity profiles created
during the IMRT optimization process is performed by
sophisticated mechanical and computerized delivery systems
on a linear accelerator. Quality assurance is an integral part
of this process and is typically performed with dosimetric
verification of the leaf motion and sequencing for each
field as well as computer based verification of the dose
distribution and monitor unit settings for each field.
Outcomes with IMRT
Evidence from several single institution studies and
multiple randomized control trials demonstrate a doseresponse relationship with doses above 68 Gy associated
with improved local and biochemical control (4,7,36). A
summary of randomized dose escalation trials is found in
Table 2. Additionally, dose-volume toxicity relationships
have also been established for rectal bleeding and other GI
and GU toxicities with increased high dose associated with
increased risk of toxicity (4,37-40). IMRT is a method to
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escalate dose while achieving safe dose-volume constraints
to organs at risk.
Published in 2007, Vora et al. evaluated biochemical
control rates and prognostic factors for patients with
localized prostate cancer treated with either high-dose
IMRT or conventional-dose 3D-CRT. A total of 271
patients received 3D-CRT with a median dose of 68.4 Gy
(range, 66.0–71.0 Gy), and 145 patients received IMRT
with a median dose of 75.6 Gy (range, 70.2–77.4 Gy). Using
the ASTRO Phoenix definition, the 5-year biochemical
control rate was 74.4% for 3D-CRT and 84.6% with IMRT
(P=0.033). On both univariate and multivariate analysis,
increased dose was associated with improved biochemical
control (19).
Despite improvements in prostate RT and increased
dose conformity, rectal complications have not been
eliminated and rectal toxicity remains a major concern for
men undergoing EBRT. Giordano et al. (41) performed
a population based analysis using the SEER database to
determine the rates and predictors of late lower GI toxicity
after prostate radiation prior to the IMRT era. They
compared a group of men with prostate cancer treated with
EBRT (n=24,130) compared to those treated without RT
(n=33,835) from 1992 to 1999. For patients with a minimum
of 5 years follow-up, the rates of GI diagnoses were 19.4%
higher in the radiation group (41). Hemorrhage was the
most common complication, and was increased by 19%
for patients treated with radiation (39.6% of RT patients
vs. comparison rates of 18.2% in patients treated with
radical prostatectomy and 20.7% in patients with no local
therapy) (41). Several single institutional series have
reported a reduction in late toxicity since the introduction
of IMRT as compared to conventional RT.
Jani et al. reviewed the records of 461 patients with
localized prostate who received either IMRT (n=106) or
conventional RT defined as 4- or 6-field conformal therapy
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(n=355) from 1998 to 2005 (42). Late GI toxicities were
found to be lower with IMRT (P<0.001) and regression
analyses demonstrated that IMRT was the only factor
predictive of late GI toxicity. On analysis of the DVH data,
it was hypothesized that the GI toxicity rates were lower
for the IMRT group due to lower mid-to-high range rectal
dosimetric metrics (V40, V50, V60, and V70). There was
no association of decreased GU complications with IMRT
compared to conventional treatment (42).
Sanguineti et al. compared the late rectal toxicity rates
after 3D-CRT to the prostate alone and whole-pelvis IMRT
along with a prostate boost to the same nominal total dose
to the prostate in both groups (43). Sixty-eight patients
were treated to the prostate alone using 3D-CRT to a total
dose of 76 Gy. A second group of patients consisted of
45 patients treated with IMRT covering the pelvic lymph
nodes and seminal vesicles to 54 Gy in 1.8 Gy fractions and
the prostate to 60 Gy in the same 30 fractions followed by
a boost to the prostate alone to 76 Gy (43). Planning was
similar for both groups, with both receiving 76 Gy to the
prostate, with the main difference being the inclusion of the
pelvic lymph nodes in the IMRT group (43). Late toxicity
was prospectively scored using the RTOG scale and all
patients had a minimum of 12 months follow-up. At 2-years,
the cumulative incidence of grade 2 late rectal toxicity was
greater for the group receiving 3D-CRT (21.2%±6%)
compared to IMRT (6%±4%) despite the IMRT group
receiving treatment to the pelvic lymph nodes. On
multivariate analysis the difference was statistically in favor
of IMRT [hazard ratio (HR): 0.1; 95% CI, 0.0–0.6; P=0.01].
No patients in either group developed grade 3+ toxicity (43).
Wortel et al. analyzed the late side effects after treatment
with image-guided (IG)-IMRT or 3D-CRT, evaluating
2 prospective cohorts of men treated with localized
prostate cancer to investigate hypothesized reductions in
toxicity (44). Patients from two Dutch randomized trials
were treated with 3D-CRT (n=189) or IG-IMRT (n=242) to
78 Gy in 39 fractions with identical toxicity scoring
protocols (modified RTOG-EORTC scoring criteria).
The 5-year cumulative incidence of grade ≥2 GI toxicity
was 24.9% for IG-IMRT and 37.6% following 3D-CRT
(adjusted HR: 0.59, P=0.005). There was significant
reduction in proctitis (HR: 0.37, P=0.047) and increased
stool frequency (HR: 0.23, P<0.001). GU grade ≥2 toxicity
remained comparable between the two groups. Other
predictors of late grade ≥2 complications were baseline
complaints, acute toxicity, and age (44).
The RTOG 0126 was a prospective randomized phase
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III trial comparing escalated high dose RT to conventional
dose RT for localized early stage intermediate risk
prostate cancer which opened in March 2002 and closed
to accrual in 2008. The primary endpoint of the study
was to determine whether 3D-CRT or IMRT to 79.2 Gy
in 44 fractions would lead to improved overall survival in
patients with intermediate risk prostate cancer compared
to those patients treated with the same techniques to
70.2 Gy in 39 fractions. The protocol initially included
only 3D-CRT, however, in September 2003 the trial was
amended to allow IMRT, and treatment modality was added
as a stratification variable in order to help avoid treatment
arm modality imbalances. Of the 1,532 patients enrolled on
the trial, 763 were randomized to the high dose treatment
arm. In this arm, patients treated with 3D-CRT received
55.8 Gy to a planning target volume that included the
prostate and seminal vesicles, and then a 23.4 Gy boost to
the prostate alone. Patients receiving IMRT were treated
to the prostate and seminal vesicles to 79.2 Gy. In 2013,
a preliminary toxicity analysis of 3D-CRT versus IMRT
was published reporting acute and late effects between the
two techniques (8). 748 of the 763 patients were eligible
of whom 491 received 3D-CRT and 257 received IMRT.
After dosimetric analysis, the median % of the bladder
receiving at least xGy (pVx equals partial volume receiving
‘x’ Gray) for pV65, pV70 and pV75 were 25.3%, 22.2%,
and 17.7% for 3D-CRT and 19.7%, 16.6% and 13.1% for
IMRT. The median rectum pV65, pV70 and pV75 were
27.4%, 21.7%, and 15.8% for 3D-CRT and 23.0%, 18.2%
and 13.0% for IMRT. For both the bladder and rectum,
the volumes receiving 65, 70, and 75 Gy were significantly
lower in the IMRT cohort (all P<0.0001). For grade 2+
acute GI/GU toxicity, both univariate and multivariate
analyses showed a significant decrease in collective GI/
GU toxicities in favor of IMRT. There was no significant
difference between 3D-CRT or IMRT for acute or late
grade 2+ or 3+ GU toxicities. Univariate analysis indicated a
statistically significant decrease in late grade 2+ GI toxicity
for IMRT (P=0.039). In multivariate analysis, IMRT had
a 26% reduction in late grade 2+ GI toxicity compared
to 3D-CRT (P=0.099). Additionally, small volumes of
the rectum exceeding high threshold radiation doses (i.e.,
>70 Gy) were associated with nearly a two-fold risk of late
grade 2 or greater toxicity. If more than 10% or 15% of the
rectum volume exceeded 75 or 70 Gy, respectively, patients
had a significantly greater risk of late GI toxicity. After both
modality and the dose thresholds were included in the GI
toxicity analysis, there was still a separation between the 3D
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and IMRT arms at each dose constraint level with a larger,
however not statistically significant, separation for the
>10% dose constraint groups. Based on these preliminary
findings of RTOG 0126, IMRT is associated with a
significant reduction in acute grade 2+ GI/GU toxicity and
there is a trend for a clinically meaningful reduction in late
grade 2+ GI toxicity with IMRT. The occurrence of acute
GI toxicity and large (>15%) volumes of rectum >70 Gy are
associated with late rectal toxicity. The final results of this
trial are pending publication this year.
In September 2017, a national population based study
was performed comparing treatment-related toxicity in
men who received IMRT versus 3D-CRT for prostate
cancer (45). Patients treated for prostate cancer between
January 2010 and December 2013 in the English National
Health Service were included (N=23,222). A total of 16,289
patients treated with 3D-CRT and 6,933 patients with
IMRT. Patients with severe toxicity, defined as at least grade
3 according to the National Cancer Institute Common
Terminology Criteria for Adverse Events scoring system
were identified. A competing risks regression analysis was
used to estimate HRs, comparing the incidence of severe GI
and GU complications after IMRT and 3D-CRT, adjusting
for patient, disease, and treatment characteristics. The use
of IMRT, as opposed to 3D-CRT, increased from 3.1% in
2010 to 64.7% in 2013 in this cohort. Patients who received
IMRT were less likely than those receiving 3D-CRT to
experience severe GI toxicity [4.9 vs. 6.5 per 100 personyears; adjusted HR: 0.66; 95% confidence interval (CI),
0.61–0.72]. Similar rates of GU toxicity were observed (2.3
vs. 2.4 per 100 person-years; adjusted HR: 0.94; 95% CI,
0.84–1.06) (45).
Lastly, a meta-analysis of 23 studies (n=9,556) comparing
the clinical outcomes, including GI toxicity, GU toxicity,
biochemical control and overall survival was performed (46).
IMRT was significantly associated with decreased grade
2–4 acute GI toxicity (risk ratio =0.59 (95% CI, 0.44–0.78),
late GI toxicity (risk ratio =0.54, 95% CI, 0.38–0.78), late
rectal bleeding (risk ratio =0.48, 95% CI, 0.27–0.85), and
achieved better bio-chemical control (risk ratio =1.17, 95%
CI, 1.08–1.27) in comparison with 3D-CRT (46). IMRT
and 3D-CRT remained the same in regard to grade 2–4
acute rectal toxicity (risk ratio =1.03, 95% CI, 0.45–2.36),
late GU toxicity (risk ratio =1.03, 95% CI, 0.82–1.30) and
overall survival (risk ratio =1.07, 95% CI, 0.96–1.19), while
IMRT slightly increased the morbidity of grade 2–4 acute
GU toxicity (risk ratio =1.08, 95% CI, 1.00–1.17) (46).
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IMRT for pelvic lymph node radiation
A subset of patients with prostate cancer, typically those
with high risk disease, may benefit from radiation to
the pelvic lymph nodes in addition to the prostate and
proximal seminal vesicles. In these situations, the use of
IMRT might also be beneficial in reducing toxicity in
comparison to 3D-CRT. Although no randomized study
has been conducted in prostate cancer comparing 3D-CRT
and IMRT techniques in treating the pelvic lymph nodes,
some insight can be gained from extrapolating from other
disease sites in which pelvic nodal coverage is indicated.
For instance, the multi-national TIME-C study enrolled
278 patients with endometrial or cervical cancer and
randomized the patients after surgery to IMRT or fourfield pelvic radiation treatment and evaluated patients
using the Expanded Prostate Cancer Index Composite
(EPIC) (47). A preliminary presentation of the toxicity
outcomes at ASTRO in 2016 suggested that IMRT reduced
GI toxicity including diarrhea and fecal incontinence
compared to 3D-CRT (47). Patients receiving IMRT
also had smaller declines in EPIC urinary domain scores.
Limitations in extrapolating data from this study to
patients with prostate cancer includes the fact that patients
in TIME-C received prior surgery, a subset received
concurrent chemotherapy, and the volumes treated with
radiation for gynecological tumors may differ from that for
prostate cancer.
Additional insight on IMRT to the pelvic volume
may be gained by examining retrospective and single
arm prospective studies in prostate cancer. A dosimetric
study by Guckenberger et al. compared the risk of toxicity
using normal tissue complication probability (NTCP)
calculations after IMRT to the prostate only compared to
additional irradiation of the pelvic lymphatic region in a
retrospective cohort of 10 patients (48). They concluded
from this planning study that the NTCP model predicted
similar risks of rectal (5–8%) and bladder (1%) toxicity
after prostate-only or prostate and pelvis IMRT. However
the risk of toxicity to the small bowel was estimated to be
increased with inclusion of the pelvic volume IMRT to
0.8–3.2%. Deville et al. retrospectively compared patients
treated with dose-escalated IMRT to 79.2 Gy to the
prostate alone or also with 45 Gy by IMRT to the pelvis (49).
Although the acute grade 2+ GI toxicity was greater with
the inclusion of pelvic radiation (50% vs. 13%), there was
no difference in late GI or GU toxicity with the addition of
pelvic IMRT (49). These estimated risks are also similar to
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the observed toxicity reported in a phase 1–2 study of doseescalated IMRT to the prostate and pelvic nodes reported
by Reis Ferreira et al. (50). They enrolled 447 patients with
locally advanced prostate cancer and treated with IMRT
of 70–74 Gy to the prostate and dose escalated IMRT to
the pelvic lymph nodes to 50–60 Gy. The 2-year rates of
grade 2+ bowel and bladder toxicity in patients receiving
conventionally fractionated pelvic IMRT ranged from
8.3–13.2% and 2.9–5.9% respectively. The importance of
reducing toxicity is especially important as it is becoming
recognized that larger radiation fields such as those
extending to L4/L5 may be necessary to adequately cover
the lymph node regions commonly involved with prostate
cancer metastasis (51).
In the setting of modern dose escalation and androgen
depravation therapy, the benefit of pelvic nodal irradiation
in patients with unfavorable intermediate risk and high risk
prostate cancer is still debatable. RTOG 0924 is an ongoing
study investigating the benefit of pelvic radiation in addition
to ADT and prostate dose escalation (52). Although both
3D-CRT and IMRT is allowed for the pelvic field, it is
expected that most of the patients will be treated with
IMRT. Outcomes and toxicity data from this randomized
study will better define the benefit and risks of covering the
nodal regions with IMRT in prostate cancer.
Future directions
As described above, clinical studies suggest that prostate
cancer has biologic characteristics which may make
it more sensitive to larger doses per fraction (i.e.,
hypofractionation) (27,53). These higher doses per fraction
may lead to better tumor kill compared to conventional
fractionation while offering increased patient convenience
from a shorter course of treatment and also fewer burdens
on the health care system with decreased treatment costs.
The CHHiP trial (a randomized, phase 3, non-inferiority
trial) demonstrated that hypofractionated radiotherapy
with IMRT using 60 Gy in 20 fractions is non-inferior to
conventional fractionation using 74 Gy in 37 fractions and
is recommended as a new standard of care for externalbeam radiotherapy of localized prostate cancer (54).
Further hypofractionation, specifically stereotactic body
radiation therapy (SBRT) which uses even larger doses per
fraction, are currently under investigation. RTOG 0938 is
a randomized phase II trial of hypofractionated radiation
therapy for favorable risk prostate cancer in which patients
are assigned to either 36.25 Gy in 5 fractions (7.25 Gy
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per fraction) versus 51.6 Gy in 12 fractions (4.3 Gy per
fraction) (55). This protocol requires the use of IMRT
or related technologies (i.e., Tomotherapy/VMAT/
Cyberknife and proton therapy) given the large doses per
fraction and risk to healthy pelvic organs (55).
Additional methods to improve the toxicity profile of
IMRT for prostate cancer are the use of a hydrogel spacer.
Given that the prostate and rectum are often in immediate
physical contact, even the most conformal IMRT plan
cannot always spare high dose radiation being delivered to
the rectum. An absorbable hydrogel injected between the
prostate and rectum has been shown in a randomized trial
to have a clinically significant 25% reduction in the rectal
V70 Gy in >97% of men, correlating with a reduction in
rectal toxicity, improvement in bowel quality of life, and
improved sexual function (56-59).
Conclusions
Radiation therapy for prostate cancer has evolved
dramatically over the past 2 decades. Treatment has
evolved from X-ray fields based on bony anatomy to dose
escalated radiation therapy with image-guidance and
IMRT. Published dose-volume constraints that can reduce
or prevent rectal injury have been established and are
achievable with IMRT. Multiple randomized, retrospective,
and population based studies have shown that men who
receive radiation therapy using IMRT were less likely to
experience severe GI toxicity compared with those who
received 3D-CRT. The radiobiology of prostate cancer also
suggests it may be more responsive to hypofractionated
treatment, and IMRT is a method to deliver higher doses
per fraction while minimizing dose to organs at risk.
Randomized trials investigating extreme hypofractionation
(SBRT) are underway.
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